Margarita N. Sinkova

Margarita N. Sinkova

Auto-generated profile, based on publicly available information

Margarita N. Sinkova

Kemerovo State Medical University

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2022 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
EPE. Yu. Plotnikova
E. Yu. Plotnikova
МСМ. Н. Синькова
М. Н. Синькова
LIL. K. Isakov
L. K. Isakov
Asthenia and fatigue are the most common syndromes in patients with liver disease, which significantly affects their quality of life. The prevalence of fatigue in chronic liver diseases is from 50% to 85%. While some progress has been made in understanding the processes that can cause fatigue in general, the underlying causes of fatigue associated with liver disease remain not well understood. In particular, many data suggest that fatigue associated with liver disease likely results from changes in neurotransmission in the brain against the background of hyperammonemia. Hyperammonemia is a metabolic state characterized by an increased level of ammonia, a nitrogen-containing compound. The present review describes hyperammonemia, which is likely important in the pathogenesis of fatigue associated with liver disease. Ammonia is a potent neurotoxin, its elevated blood levels can cause neurological signs and symptoms that can be acute or chronic, depending on the underlying pathology. Hyperammonemia should be recognized early, and immediately treated to prevent the development of life-threatening complications, such as, swelling of the brain and coma. The article gives pathophysiological mechanisms of influence of hyperammonemia on state of psychovegetative status of patients with liver diseases, also lists basic principles of treatment. A significant part of the article is devoted to L-ornithine-L-aspartate, which is effective in asthenia and fatigue to reduce the level of hyperammonemia through a variety of well-studied mechanisms in chronic liver diseases.

11 October 2019 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
EPE. Yu. Plotnikova
E. Yu. Plotnikova
TGT. Yu. Gracheva
T. Yu. Gracheva
МСМ. Н. Синькова
М. Н. Синькова
LIL. K. Isakov
L. K. Isakov
Psyllium is a predominantly soluble fiber among other natural plant-based dietary fiber used in food and pharmaceuticals and is sold as a laxative fiber. Isphagula (lat. ispaghula)– international nonproprietary name of a medicine of «psyllium». Accordingly to ATX belongs to the group of «Laxatives», subgroup «A06AC «Laxatives increasing volume of intestinal contents» (Bulking laxatives) and has the following code and name: «A06AC01 «Ispaghula» (plantain oval seeds)». Isphagula is a medical dietary fiber; in the context of gastrointestinal problems in terms of «ispaghula» and «psyllium» are synonymous. Psyllium flour has virtually no digestible carbohydrates. This fact is a significant advantage of psyllium over oat bran, in which such carbohydrates are more than 60%. A distinctive feature of psyllium is that it is almost completely (80–85%) consists of fiber (about 70% of which is soluble), which in contact with water turns into a soft gel. Only 1 gram of fiber ground fiber flour is able to absorb up to 45 ml of water. In the colon, psyllium is resistant to fermentation, remains intact in the feces and significantly increases the water content in the feces, providing a laxative effect. Psyllium softens hard stools in constipation, normalizes loose stools in diarrhea, and normalizes stool shape in patients with IBS, relieving gastrointestinal symptoms. Dietary supplement «Fitomucil® Norm» contains 4.5 g of psyllium (Plantago psyllium), and dry pulp of prunes (Prunus domestica) – 0.5 g. This combination of psyllium and prunes can be widely used in patients with constipation and other functional digestive disorders in different age groups, including pregnant and lactating women, as a first-line remedy.

29 September 2018 in Bulletin of Siberian Medicine
Verified
Journal Article
Open access
PDF file
ATA. T. Teplyakov
A. T. Teplyakov
NTN. I. Tarasov
N. I. Tarasov
LIL. K. Isakov
L. K. Isakov
Elena GrakovaElena Grakova
Elena Grakova
МСМ. Н. Синькова
М. Н. Синькова
EKE. V. Kalyuzhina
E. V. Kalyuzhina
Aim.The purpose of this study was to examine the association of increasing concentrations of endothelin-1 and soluble forms of ST2 protein (sST2) in the blood plasma of patients with chronic heart failure (CHF) who underwent implantation of a cardioverter-defibrillator, with the development of cardiovascular events (death from cardiovascular diseases, decompensated CHF, acute coronary syndrome or acute ischemic stroke) to determine whether these biomarkers can be used as predictors of an unfavorable course of the disease.Material and methods. A 6-month cohort study included 40 patients with CHF who received an ICD 4-12 weeks before their inclusion in the study. At the beginning of the study the concentrations of endothelin-1 and sST2 in plasma by ELISA were analyzed, along with conventional diagnostic techniques typical of a specialized cardiology clinic.Results.Phenotype with a favorable course of the disease was identified in 21 patients (group 1), and with a unfavorable course was seen in 19 (group 2). The concentration of endothelin-1 and sST2 in the blood plasma of the 2nd group patients was higher than in patients of the 1st group. The link of cardiovascular events with high levels of soluble ST2 protein and endothelin-1 in blood plasma has been identified. Variation of the decision rule threshold on the ROC-curve has allowed sST2 concentration of 34.93 ng/ml to be determined as a cutoff point. Accuracy of two-class classification (determination of the posterior probability of cardiovascular events) after identifying such cut-off point was characterized by 93% sensitivity and 72% specificity (area under ROC-curve – 0.87). If the value of the plasma concentrations of sST2 more 34.93 ng/ml the relative risk of cardiovascular events was 4.4 (95% CI 1.7–11.1). The use of endothelin-1 surplus in plasma (cut-off point – 0.34 fmol/ml) in predicting cardiovascular events was lower: the sensitivity – 88%, specificity – 68% (area under ROC-curve – 0.74). When the concentration of endothelin-1 in blood plasma was more than 0.34 fmol/ml the relative risk of cardiovascular events was 2.7 (95% CI 1.2–6.3).Conclusion.The increase in the sST2 and endothelin-1 concentration in blood plasma may be considered as a predictor of cardiovascular events in CHF patients after implantation of cardioverter-defibrillator.

9 August 2022 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
Elena GrakovaElena Grakova
Elena Grakova
KKK. V. Kopyeva
K. V. Kopyeva
ATA. T. Teplyakov
A. T. Teplyakov
LIL. K. Isakov
L. K. Isakov
МСМ. Н. Синькова
М. Н. Синькова
NTN. I. Tarasov
N. I. Tarasov
Aim. To assess the prognostic role of cardiac biomarkers (galectin-3, soluble ST2 (sST2), and N-terminal pro-brain natriuretic peptide (NT-proBNP)) in risk stratification of adverse cardiovascular events (CVEs) in patients with heart failure (HF) after implantation of an automatic implantable cardioverter-defibrillator (AICD) within 12-month follow-up period.Material and methods. The study included 57 patients (men, 41; mean age, 65 (59; 68) years) with coronary artery disease and NYHA class II-III HF with left ventricular ejection fraction of 34 [26; 40]%. All patients were implanted with AICD. Serum levels of NT-proBNP, sST2, and galectin-3 were determined by enzyme immunoassay prior to AICD implantation.Results. It has been established that in order to stratify the risk of unfavorable HF in patients after AICD implantation for 12-month follow-up, all three studied biomarkers can be considered as prognostic factors. Thus, an increase in the level of NT-proBNP ≥1046,6 pg/ml (AUC=0,68; p=0,009), sST2 ≥34,43 ng/ml (AUC=0,78; p<0,0001) and galectin-3 ≥11,6 ng/l (AUC=0,72; p=0,0014) predicts a high risk of adverse CVEs. The combination of sST2 and galectin-3 increased the predictive value of the analysis (AUC=0,84; p<0,0001), while the addition of NTproBNP did not increase the accuracy of risk stratification.Conclusion. The determination of the combination of galectin-3 and sST2 can potentially help identify a group of patients with HF after AICD implantation with a high risk of adverse CVEs for intensification and optimization of treatment.

15 October 2020 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
МСМ. Н. Синькова
М. Н. Синькова
LIL. K. Isakov
L. K. Isakov
МСМ. А. Синьков
М. А. Синьков
EPE. Yu. Plotnikova
E. Yu. Plotnikova
EGE. N. Gulyaeva
E. N. Gulyaeva
Новое в реабилитации больных с хронической сердечной недостаточностью, ассоциированной с сахарным диабетом 2-го типа

30 December 2025 in Complex Issues of Cardiovascular Diseases
Verified
Journal Article
Closed access
TPTamara Pecherina
Tamara Pecherina
MSMargarita N. Sinkova
Margarita N. Sinkova
YGYulia I. Guselnikova
Yulia I. Guselnikova
OBOlga Barbarash
Olga Barbarash
Highlights Understanding the interaction between various diseases in patients with acute heart failure and acute decompensated heart failure is key to developing effective prevention and management strategies aimed at improving the quality of medical care and reducing morbidity and mortality among this group of patients. Abstract Acute decompensated heart failure (ADHF) is a serious clinical condition that is often accompanied by multimorbidity, i.e. the presence of several chronic diseases simultaneously. These comorbidities significantly complicate the diagnosis, treatment and prognosis of outcomes in patients with ADHF. The review considers the most common comorbid conditions, such as arterial hypertension, diabetes mellitus, chronic kidney disease, obesity, depression and cognitive impairment. Each of these factors individually, as well as together (synergistically), affects the course of ADHF, increasing the risk of complications and worsening the patient's quality of life. Emphasizes the importance of an integrated approach to the management of patients with ADHF and multimorbidity. Early detection and pathogenetic therapy of comorbidities can reduce the frequency of hospitalizations, improve the functional capabilities of patients and increase life expectancy. Thus, understanding the interactions between various diseases in patients with ADHF is key to developing effective prevention and treatment strategies aimed at improving the quality of medical care and reducing morbidity and mortality in this group of patients.